6533b85dfe1ef96bd12be9ec

RESEARCH PRODUCT

Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?

Enrique GrandeAngelo MartignettiMatteo SantoniRodolfo MontironiMarc R. MatranaAlessia CimadamoreUmberto BassoUgo De GiorgiGaetano AurilioSimon J. CrabbMichele MilellaSergio BracardaNuno VauFrancesco MassariGiacomo CartenìMimma RizzoGiuseppe ProcopioNicola BattelliLorena IncorvaiaGiulia Sorgentoni

subject

0301 basic medicinemedicine.medical_specialtyPrognostic factorobesityrenal cell carcinomaMultivariate analysisCabozantinibPrognosiClinical Biochemistrybody mass indexurologic and male genital diseasesGastroenterologyArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRenal cell carcinomacabozantinibInternal medicinemedicineOverall survivalIn patientneoplasmsPathologicallcsh:R5-920real-world databusiness.industrybody mass index; cabozantinib; obesity; prognosis; real-world data; renal cell carcinoma; targeted therapymedicine.diseasetargeted therapyfemale genital diseases and pregnancy complications030104 developmental biologychemistry030220 oncology & carcinogenesisprognosislcsh:Medicine (General)businessBody mass index

description

We analyzed the clinical and pathological features of renal cell carcinoma (RCC) patients treated with cabozantinib stratified by body mass index (BMI). We retrospectively collected data from 16 worldwide centers involved in the treatment of RCC. Overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan&ndash

10.3390/diagnostics11010138http://europepmc.org/articles/PMC7831923